AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04731389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life improving intervention
Description: consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
Study NCT05625321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Group Weight Loss Classes
Description: Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
Study NCT05625321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Group Weight Loss Classes
Description: Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
Study NCT05625321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Gardening Intervention
Description: Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
Study NCT05664867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mainstream Genetic Testing Model
Description: Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
Study NCT06350188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: 15 patients ˃receive kinisio-tape ,2 session / week for 2 weeks. Followed by stretching exercises, they will be assessed pre and immediately post application, after two weeks and follow up after one month
Study NCT06350188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional
Description: 15 patients ˃ will receive ischemic pressure release followed by stretching exercises 2 session / week for 2 weeks, will be assessed pre and immediately post application, after two weeks and follow up after one month.
Study NCT06011408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TDtect
Description: Collecting video data on abnormal movement
Study NCT06451302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide
Description: The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
Study NCT05355103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational tool about epidural analgesia
Description: See arm description
Study NCT05664867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care Model
Description: Enhanced Standard of Care Model of Cancer Genetic Service Delivery
Study NCT04968158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg / Tramadol 50 mg
Description: One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
Study NCT04968158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 325 mg / Tramadol 37.5 mg
Description: One tablet, every 8 hours of 325 mg/ 37.5 m
Study NCT05183945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Localization needle
Description: A localization needle which is used for preoperative localization of lung nodules.
Study NCT05183945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coil
Description: A coil which is used for preoperative localization of lung nodules.
Study NCT04662008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-coaching
Description: This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
Study NCT04662008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
Study NCT04847843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Orientated Recovery Enhancement
Description: The MORE curriculum has been adapted for this intervention to address food intake behaviors and will provide training in mindfulness techniques to increase awareness of, and self-control over, cravings; reappraisal skills to promote emotion regulation and restructure motivations for highly palatable food intake; and savoring pleasant events and emotions to overcome defects in natural reward processing.
Study NCT04847843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The curriculum will be based on the Diabetes Prevention Program's Prevent T2 for Life program, which is an evidence-based national healthful lifestyle maintenance intervention. This program includes training in healthful eating, meal planning, and recipe modification; time and stress management; adapting lifestyle habits for continued success during holidays, vacations, and other special situations; and relapse prevention.
Study NCT06055179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao Chai Hu Tang (XCHT)
Description: XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
Study NCT06055179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
Study NCT06055179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan regimen
Description: Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks.
Study NCT06055179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan regimen
Description: Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks.
Study NCT06055179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
Study NCT06055179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
Study NCT05843825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical placement of dental implants
Description: Three dental implants were placed (one anterior in midline area and two posterior at first molar area).
Study NCT05843825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overdenture supported by locator attachment system
Description: Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer
Study NCT05563285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Mindfulness-Based Intervention
Description: 1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running
Study NCT05563285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Mindfulness-Based Intervention
Description: 1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running
Study NCT05563285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
Study NCT05563285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
Study NCT04876235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasound
Description: All patients were implanted with stents（DPPS or LAMS）under the EUS
Study NCT04876235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound
Description: All patients were implanted with stents（DPPS or LAMS）under the EUS
Study NCT04876235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lumen-apposing metal stent
Description: In the LAMS group, patients were stented with LAMS
Study NCT04876235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double-pigtail plastic stents
Description: In the DPPS group, patients were stented with DPPS
Study NCT04812275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin closure
Description: Skin closure
Study NCT04812275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin closure
Description: Skin closure
Study NCT05902156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DiaPaDeSS
Description: Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
Study NCT05902156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DiaPaDeSS
Description: Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
Study NCT04788381 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
Study NCT05337085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
Study NCT05337085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study NCT05829356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3 mRNA / LNP Vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular
Study NCT05829356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent recombinant influenza Vaccine (RIV4)
Description: Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular
Study NCT04705207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reflexology massage
Description: the patient receive only foot reflexology massage
Study NCT04705207 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham massage
Description: the patient receive only foot traditional massage
Study NCT05420285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
Study NCT04839939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training
Study NCT04839939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis
Description: Solid prescribed AFO with a wearing schedule of 6-12 hours per day
Study NCT05607537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386 Tablet
Description: E7386 40 mg tablet.
Study NCT05607537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (14C)E7386 Capsule
Description: (14C)E7386 40 mg capsule.
Study NCT05607537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (14C)E7386
Description: (14C)E7386 administered intravenously.
Study NCT04839939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Taping
Description: Combination between elastic and inelastic taping
Study NCT06185465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan Wound Irrigation Solution
Description: After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
Study NCT06185465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
Study NCT05971550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absence of antibiotic treatment
Description: Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
Study NCT05971550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
Study NCT04896528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: * Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment.
Study NCT04992117 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study NCT06472674 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04872361 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low PEEP
Description: Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
Study NCT04872361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP
Description: PEEP of 10 cm H2O will be applied
Study NCT04872361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP/RM
Description: PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
Study NCT04872361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasonogrphy assessment
Description: The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss
Study NCT04872361 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasonogrphy assessment
Description: The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss
Study NCT06268652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organoid-guided personalized treatment
Description: After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.
Study NCT06268652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2，IV, days 1, 8, q3w
Study NCT06268652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m² , PO, bid, days1-14, q3w
Study NCT06268652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w
Study NCT06268652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4mg/m², IV, days 1 and 8, q3w
Study NCT05668832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UVB-exposed button mushrooms
Description: Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
Study NCT05668832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UVB-exposed button mushrooms
Description: Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.